HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Google Scholar Articles by Kapoor, S. PubMed PubMed Citation Articles by Kapoor, S. Related Collections Lung - basic science Lung - other Cardiac - physiology

Letters to the Editor

Sivelestat and its role in tissue reperfusion injury

University of Illinois at Chicago, Chicago, IL 60612, United States

Received 7 January 2008; accepted 11 March 2008.

^_* Corresponding author. Address: University of Illinois at Chicago, Chicago, IL 60612, United States. (Email: shailendrakapoor{at}yahoo.com).

Key Words: Sivelestat • Tissue reperfusion injury • Multiple organ failure

The recent article by Mori et al. is highly interesting [1]. Recent studies have shown that sivelestat decreases and prevents tissue reperfusion injury not just in the lung but in other organs also.

For instance, Kotake et al. have recently shown that sivelestat can effectively decrease the effects of ischemia reperfusion injury in the hepatoenteric region [2]. Similarly, it has been shown that sivelestat attenuates the effects of ischemia reperfusion injury in the bladder [3]. Kambe et al. have even reported that sivelestat decreases myocardial damage secondary to tissue reperfusion injury in the heart [4]. These beneficial effects were noted even if the drug was administered after the onset of the myocardial ischemia. In another recent study, Hoshi et al. compared the mortality in critically ill patients admitted in an intensive care unit who were treated with sivelestat to the mortality in those who did not receive sivelestat [5]. The mortality in critically ill patients who were treated with sivelestat was 6% compared to 33.3% in those who did not receive sivelestat therapy.

These studies clearly indicate that sivelestat may have a major role to play in the management of tissue reperfusion injury, especially in patients with multiple organ failure, in the near future. Further studies, especially in humans, are needed so as to fully avail these beneficial effects.

Footnotes

The authors of the original paper [1] were invited to reply to this Letter to the Editor but they did not respond.

References

1. Mori H, Nagahiro I, Osaragi T, Kotani K, Nakanishi H, Sano Y, Date H, Shimizu N. Addition of a neutrophil elastase inhibitor to the organ flushing solution decreases lung reperfusion injury in rat lung transplantation. Eur J Cardiothorac Surg 2007;32:791-795.[Abstract/Free Full Text]
2. Kotake Y, Yamamoto M, Matsumoto M, Morisaki H, Takeda J. Sivelestat, a neutrophil elastase inhibitor, attenuates neutrophil priming after hepatoenteric ischemia in rabbits. Shock 2005;23:156-160.[CrossRef][Medline]
3. Kono T, Okada SI, Saito M. Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia-reperfusion injury in the rat bladder. Mol Cell Biochem 2007.
4. Kambe M, Bessbo R, Fujii M, Ochi M, Shimizu K. Myocardial protection: The efficacy of sivelestat sodium, as an inhibitor of reperfusion injury. J Mol Cell Card 2007;42:S204.
5. Hoshi K, Kurosawa S, Kato M, Andoh K, Satoh D, Kaise A. Sivelestat, a neutrophil elastase inhibitor, reduces mortality rate of critically ill patients. Tohoku J Exp Med 2005;207:143-148.[CrossRef][Medline]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Google Scholar Articles by Kapoor, S. PubMed PubMed Citation Articles by Kapoor, S. Related Collections Lung - basic science Lung - other Cardiac - physiology